GEM 1.5 mg b.i.d. to 4.5 mg b.i.d. Versus Lorazepam in GAD
Information source: Merck
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Anxiety Disorder
Intervention: MK0777 (Drug)
Phase: Phase 2
Status: Completed
Sponsored by: Merck Official(s) and/or principal investigator(s):
Medical Monitor, Study Director, Affiliation: Merck
Summary
This study will determine the effectiveness of MK0777 GEM versus Lorazepam in the treatment
of patients with generalized anxiety disorder.
This is an early phase trial and some specific protocol information is in progress and not
publicly available at this time. (Full information is available to trial participants).
Clinical Details
Study design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Eligibility
Minimum age: 18 Years.
Maximum age: 70 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Have been diagnosed with Generalized Anxiety Disorder
- Women of childbearing potential must use a double-barrier methods of contraception and
must have a negative blood pregnancy test at the beginning of the study
Exclusion Criteria:
- History of drug or alcohol abuse
- Have previously participated in another study using MK0777
Locations and Contacts
Additional Information
Starting date: November 2002
Ending date: December 2003
Last updated: October 17, 2007
|
